Organon & Co. (NYSE:OGN – Get Free Report) and Aditxt (NASDAQ:ADTX – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Organon & Co. and Aditxt, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Organon & Co. | 2 | 5 | 0 | 0 | 1.71 |
| Aditxt | 1 | 0 | 0 | 0 | 1.00 |
Organon & Co. presently has a consensus target price of $11.40, indicating a potential downside of 17.06%. Given Organon & Co.’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Organon & Co. is more favorable than Aditxt.
Volatility & Risk
Organon & Co. has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500. Comparatively, Aditxt has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500.
Earnings & Valuation
This table compares Organon & Co. and Aditxt”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Organon & Co. | $6.22 billion | 0.58 | $187.00 million | $0.77 | 17.85 |
| Aditxt | $14,336.00 | 0.06 | -$41.71 million | ($100,788.35) | -0.00 |
Organon & Co. has higher revenue and earnings than Aditxt. Aditxt is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Organon & Co. and Aditxt’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Organon & Co. | 3.41% | 88.97% | 6.03% |
| Aditxt | -360,152.50% | -374.60% | -105.93% |
Institutional & Insider Ownership
77.4% of Organon & Co. shares are owned by institutional investors. Comparatively, 15.5% of Aditxt shares are owned by institutional investors. 1.6% of Organon & Co. shares are owned by company insiders. Comparatively, 0.0% of Aditxt shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Organon & Co. beats Aditxt on 13 of the 13 factors compared between the two stocks.
About Organon & Co.
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
About Aditxt
Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.com's FREE daily email newsletter.
